Quarterly ResultMay 6, 2026, 04:02 PM
Arcutis Q1 ZORYVE Revenue $105.4M, +65% YoY
AI Summary
Arcutis Biotherapeutics reported Q1 2026 ZORYVE net product revenue of $105.4 million, marking a 65% year-over-year increase despite a 17% sequential decline attributed to typical Q1 seasonality. The company submitted a supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% to expand its indication for atopic dermatitis in infants aged 3 to 24 months and initiated a Phase 1a/1b study for ARQ-234. Arcutis also completed its dermatology sales force expansion, began building a primary care and pediatrics-focused team, and maintained positive operating cash flow of $2.2 million for the quarter.
Key Highlights
- ZORYVE Q1 2026 net product revenue was $105.4 million, a 65% increase YoY.
- ZORYVE Q1 2026 net product revenue decreased 17% QoQ due to seasonality.
- Net loss for Q1 2026 was $11.3 million, or $0.09 per basic and diluted share.
- Generated $2.2 million of positive cash flow from operating activities in Q1 2026.
- Cash, cash equivalents, and marketable securities totaled $224.3 million as of March 31, 2026.
- R&D expenses for Q1 2026 were $30.6 million, up from $17.5 million YoY.
- SG&A expenses for Q1 2026 were $74.1 million, up from $64.0 million YoY.
- Full-year 2026 net product revenue guidance remains $480 million to $495 million.